-
Paul Offit, MD, infectious disease chief at the Children's Hospital of Philadelphia, has been front and center in the fight against the growing anti-vaccine movement and he has the hate mail to prove it.
-
HIV clinicians now are advised to consider HIV antiretroviral treatment for patients who have CD4 counts greater than 350 cells/mm3 and perhaps even upon diagnosis.
-
In a study of HIV transmission, 3,408 HIV-1 serodis cordant couples were enrolled at 14 sites in Africa.
-
On Feb. 12, 2010, the Food and Drug Administration (FDA) granted tentative approval for efavirenz cross-scored tablets, 200 mg, manufactured by Strides Arcolab Limited of Bangalore, India. The cross-scored tablet can be broken into two 100 mg or four 50 mg doses to facilitate pediatric dosing.
-
-
A new study shows a continued decline in hospitalizations and emergency department visits among HIV-infected adults in the United States.
-
HIV patients in international settings where cheaper drugs are available and who are more adherent to their antiretroviral treatment cost less overall to treat than do patients who are less adherent, a new study shows.
-
A new data analysis by the Centers for Disease Control and Prevention underscores the disproportionate impact of HIV and syphilis among gay and bisexual men in the United States.
-
The HIV epidemic has converged with emerging community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), a complication that raises both new challenges and opens possible avenues to prevention, researchers report.
-
Recognizing that ED wait times and throughput are affected by the entire hospital, the leaders at King's Daughters Medical Center in Ashland, KY, engaged all the departments that interface with the ED and slashed the rate at which ED patients leave before treatment from 5% to 0.5%.
